Cynthia Rice, MPP, JDRF chief mission strategy officer, explains how Build Back Better would affect the cost of insulin.
Build Back Better could make the insulin out-of-pocket cost consistent throughout the year, said Cynthia Rice, JDRF chief mission strategy officer. JDRF is advocating for an affordable insulin provision in the proposed Build Back Better Act.
Can you discuss how the insulin price cap in Build Back Better would work?
It's $35 a month for insulin, so it's an affordable price for a life-saving drug that people need every day to stay alive. It applies to both Medicare and the commercial space, and in addition, it removes insulin from the deductible for both Medicare and the commercial space. That has the impact of making the insulin out-of-pocket cost consistent throughout the year, so in January, February, and March, it'll be the same $35 a month as in September, October, and December. That sort of predictability and affordability is what we need for people to be able to access this life-saving drug and make sure that they are being as healthy as possible until we have a cure.